Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 801–900 of 1,026
Atherton, J. J., Sindone, A. P., Pasquale, C. G. D., Driscoll, A. L., Macdonald, P. S., Hopper, I., Kistler, P. M., Briffa, T. G., Wong, J., Abhayaratna, W. P., et al. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00647 · Cited by 55
Clinical Profiles in Acute Heart Failure: An Urgent Need for a New Approach
Chapman, B., DeVore, A. D., Mentz, R. J., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12439 · Cited by 56
“Acute heart failure is a unique clinical syndrome with limited treatment options The lack of progress in the pharmacologic treatment of acute HF is in contrast to treatment advances for patients with chronic HFrEF.11,12,16 There are currently a plethora of treatment options for patients with chronic HFrEF, and this po…”
ResultInfluentialAngiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?
Mascolo, A., Urbanek, K., Angelis, A. D., Sessa, M., Scavone, C., Berrino, L., Rosano, G. M. C., Capuano, A., & Rossi, F. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09837-7 · Cited by 62
The Importance of Natriuretic Peptides in Cardiometabolic Diseases
Vinnakota, S., & Chen, H. H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa052 · Cited by 55
Zalilah, M. S., & Tham, B. L. (2002) · PubMed · Cited by 70
Lumbers, R. T., Martin, N., Manoharan, K., Nyong, J., Thomas, J., Casas, J. P., & Davies, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012721 · Cited by 56
Pandey, K. N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.693099 · Cited by 59
de Oliveira, A. A., Vergara, A., Wang, X., Vederas, J. C., & Oudit, G. Y. (2021) · Peptides · doi:10.1016/j.peptides.2021.170697 · Cited by 60
Yang, J., Grafton, F., Ranjbarvaziri, S., Budan, A., Farshidfar, F., Cho, M., Xu, E., Ho, J. J., Maddah, M., Loewke, K. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl5654 · Cited by 57
Kondo, T., Dewan, P., Anand, I. S., Desai, A. S., Packer, M., Zile, M. R., Pfeffer, M. A., Solomon, S. D., Abraham, W. T., Shah, S. J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063642 · Cited by 54
Self-citationChinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
ZHANG, S.-Y. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.03.002 · Cited by 66
Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure
Bayés‐Genís, A., Barallat, J., Pascual-Figal, D. A., Núñez, J. E., Miñana, G., Sánchez‐Más, J., Galán, A., Sanchis, J., Zamora, E., Pérez‐Martínez, M. T., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.006 · Cited by 53
Improving outcomes in heart failure: a personal perspective
McMurray, J. J. V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv565 · Cited by 62
Self-citationNatriuretic Peptides and Analytical Barriers
Vasile, V. C., & Jaffe, A. S. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.254714 · Cited by 53
Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease
Chen, Y., & Burnett, J. C. J. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.262907 · Cited by 55
Manja, V., Albashir, S. M., & Guyatt, G. H. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.12.001 · Cited by 55
Neurohormonal Blockade in Heart Failure
von Lueder, T. G., Kotecha, D., Atar, D., & Hopper, I. (2017) · Cardiac failure review · doi:10.15420/cfr.2016:22:2 · Cited by 56
Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study
Beltrán, P., Palau, P., Domínguez, E., Faraudo, M., Núñez, E., Guri, O., Mollar, A., Sanchís, J. M., Bayés‐Genís, A., & Núñez, J. E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.074 · Cited by 53
Sex-related differences in chronic heart failure
Aimo, A., Vergaro, G., Barison, A., Maffei, S., Borrelli, C., Morrone, D., Cameli, M., Palazzuoli, A., Ambrosio, G., Coiro, S., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.068 · Cited by 52
The Mechanism of Action of LCZ696
Menéndez, J. L. T. (2016) · Cardiac failure review · doi:10.15420/cfr.2016:1:1 · Cited by 59
“001).(57) Interestingly, these benefits were also observed in 2,907 patients with diabetes.”
BackgroundMethodInfluentialKhariton, Y., Fonarow, G. C., Arnold, S. V., Hellkamp, A. S., Nassif, M. E., Sharma, P. P., Butler, J., Thomas, L. E., Duffy, C. I., DeVore, A. D., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.05.016 · Cited by 56
Race, Natriuretic Peptides, and High-Carbohydrate Challenge: A Clinical Trial
Patel, N., Russell, G., Musunuru, K., Gutiérrez, O. M., Halade, G. V., Kain, V., Lv, W., Prabhu, S. D., Margulies, K. B., Cappola, T. P., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315026 · Cited by 57
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review
Proudfoot, C., Studer, R. L., Rajput, T., Jindal, R., Agrawal, R., Corda, S., & Senni, M. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.01.061 · Cited by 59
Felker, G. M., Butler, J., Ibrahim, N. E., Piña, I. L., Maisel, A. S., Bapat, D., Camacho, A., Ward, J. H., WILLIAMSON, K. M., Solomon, S. D., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054034 · Cited by 57
Self-citationA Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction
Miller, R. J. H., Howlett, J. G., & Fine, N. M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.028 · Cited by 57
Ehteshami‐Afshar, S., Mooney, L., Dewan, P., Desai, A. S., Lang, N. N., Lefkowitz, M. P., Petrie, M. C., Rizkala, A. R., Rouleau, J. L., Solomon, S. D., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019238 · Cited by 52
Self-citationSex Differences and Regulatory Actions of Estrogen in Cardiovascular System
Ueda, K., Fukuma, N., Adachi, Y., Numata, G., Tokiwa, H., Toyoda, M., Otani, A., Hashimoto, M., Liu, P., & Takimoto, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738218 · Cited by 61
“Neprilysin inhibition by ARNI that provides cardiovascular benefits also stimulates cGMP signaling via augmentation of the natriuretic peptides (McMurray et al., 2014).”
BackgroundHadwiger, M., Dagres, N., Haug, J., Wolf, M. S., Marschall, U., Tijssen, J. G. P., Katalinic, A., Frielitz, F., & Hindricks, G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac053 · Cited by 54
“Indeed, the risk of sudden cardiac death in heart failure patients has decreased over time,(3) most probably due to advances in pharmacological and non-pharmacological treatment.(36) The distribution of baseline characteristics between CRT-P and CRT-D patients in our study was similar with the distribution in previous…”
Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review
Khan, M. S., Ahmed, A. B., Greene, S. J., Fiuzat, M., Kittleson, M. M., Butler, J., Bakris, G. L., & Fonarow, G. C. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.09.013 · Cited by 56
Treatment of OSA and its Impact on Cardiovascular Disease, Part 2
Javaheri, S., Javaheri, S., Gozal, D., Campos‐Rodríguez, F., Martínez‐García, M. Á., Mokhlesi, B., Mehra, R., McNicholas, W. T., Somers, V. K., Zee, P. C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.024 · Cited by 54
Shaddy, R. E., Burch, M., Kantor, P. F., Solar‐Yohay, S., Garito, T., Zhang, S., Kocun, M., Mao, C. Y., Cilliers, A. M., Wang, X., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066605 · Cited by 64
Vascular (dys)function in the failing heart
Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 61
“…α-adrenergic receptor-derived vasoconstriction). d The reported risk estimates used the placebo group as the reference but, in the PARADIGM-HF trial 252 , the reported hazard ratios refer to the comparison between the ARNI (200 mg twice daily) and enalapril (10 mg twice daily). e Pooled analysis…”
Packer, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023538 · Cited by 55
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citationSrivastava, P. K., Claggett, B. L., Solomon, S. D., McMurray, J. J. V., Packer, M., Zile, M. R., Desai, A. S., Rouleau, J. L., Swedberg, K. B., & Fonarow, G. C. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3957 · Cited by 53
Self-citationHansen, L. H., Madsen, T. D., Goth, C. K., Clausen, H., Chen, Y., Dzhoyashvili, N. A., Iyer, S. R., Sangaralingham, S. J., Burnett, J. C. J., Rehfeld, J. F., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008102 · Cited by 54
DeJong, C., Kazi, D. S., Dudley, R. A., Chen, R., & Tseng, C. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2223 · Cited by 52
Sympathetic activation in congestive heart failure: an updated overview
Grassi, G. M., Quarti‐Trevano, F., & Esler, M. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09901-2 · Cited by 59
Krzesiński, P., Jankowska, E. A., Siebert, J., Galas, A. A., Piotrowicz, K., Stańczyk, A., Siwołowski, P., Gutknecht, P. G., Chrom, P., Murawski, P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2358 · Cited by 59
Tsigkas, G., Apostolos, A., Despotopoulos, S., Vasilagkos, G., Kallergis, E. M., Leventopoulos, G., Mplani, V., & Davlouros, P. A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10133-6 · Cited by 56
Yamamoto, K. I., & Rakugi, H. (2021) · Hypertension Research · doi:10.1038/s41440-021-00706-1 · Cited by 63
“In the PARADIGM-HF trial, S/V did not reduce the prespecified exploratory outcome of new-onset diabetes that occurred in 84 patients during the course of the PARADIGM-HF trial [5, 99].”
BackgroundMethodInfluentialCalamera, G., Moltzau, L. R., Levy, F. O., & Andressen, K. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042145 · Cited by 63
Bayés‐Genís, A., Aimo, A., Jhund, P. S., Richards, M., de Boer, R. A., Arfsten, H., Fabiani, I., Lupón, J., Anker, S. D., González, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2675 · Cited by 58
Rohde, L. E. P., Zimerman, A., Vaduganathan, M., Claggett, B. L., Packer, M., Desai, A. S., Zile, M. R., Rouleau, J. L., Swedberg, K. B., Lefkowitz, M. P., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4427 · Cited by 61
Self-citationKorean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0011 · Cited by 58
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials
Zhang, J. J., Pogwizd, S. M., Fukuda, K., Zimmermann, W., Fan, C., Hare, J. M., Bolli, R., & Menasché, P. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01098-8 · Cited by 58
“…the efficacy of a number of complementary pharmacological approaches to treat HF. Seminal RCTs, including RALES 36 , Val-HeFT 37 , PARADIGM-HF 38 and DAPA-HF 39 , showed improved survival after treatment with mineralocorticoid receptor antagonists (spironolactone and eplerenone) 36 ,…”
Mechanisms of diabetic cardiomyopathy: Focus on inflammation
Bellemare, M., Bourcier, L., Iglesies‐Grau, J., Boulet, J., O’Meara, E., & Bouabdallaoui, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16242 · Cited by 63
“78 ARNI sacubitril/valsartan has never been tested for the primary prevention of myocardial impairment in patients with T2D.”
New medical therapies for heart failure
von Lueder, T. G., & Krum, H. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.137 · Cited by 55
Epigenetic regulation in heart failure
Kim, S. Y., Morales, C. R., Gillette, T. G., & Hill, J. A. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000276 · Cited by 51
Packer, M., & McMurray, J. J. V. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30969-2 · Cited by 55
Self-citationRanek, M. J., Oeing, C. U., Sanchez‐Hodge, R., Kokkonen-Simon, K. M., Dillard, D., Aslam, M., Rainer, P. P., Mishra, S., Dunkerly-Eyring, B. L., Holewinski, R. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18980-x · Cited by 48
Carnicelli, A., Li, Z., Greiner, M. A., Lippmann, S., Greene, S. J., Mentz, R. J., Hardy, N. C., Blumer, V. L., Shen, X., Yancy, C. W., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.018 · Cited by 55
Brownell, N. K., Ziaeian, B., & Fonarow, G. C. (2021) · Cardiac failure review · doi:10.15420/cfr.2021.18 · Cited by 57
Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling
Buono, M. G. D., Garmendia, C. M., Seropian, I. M., Gonzalez, G. E., Berrocal, D. H., Biondi‐Zoccai, G., Trankle, C. R., Bucciarelli‐Ducci, C., Thiele, H., Lavie, C. J., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101215 · Cited by 61
Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure
Giustino, G., Camaj, A., Kapadia, S. R., Kar, S., Abraham, W. T., Lindenfeld, J. M., Lim, D. S., Grayburn, P. A., Cohen, D. J., Redfors, B., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.803 · Cited by 58
Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis
Foucault‐Bertaud, A., Joshkon, A., Heim, X., Bachelier, R., Bardin, N., Leroyer, A. S., & Blot‐Chabaud, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021756 · Cited by 56
Elia, A., & Fossati, S. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1060666 · Cited by 58
“Despite the advances in the medical and surgical fields, the progression of cardiac illnesses is still growing, together with the mortality rate (Florea and Cohn, 2014; McMurray et al., 2014; Shivkumar et al., 2016).”
BackgroundIbrahim, N. E., & Januzzi, J. L. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1071664 · Cited by 54
Buglioni, A., & Burnett, J. C. J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.027 · Cited by 55
Improving Heart Failure Therapeutics Development in the United States
O’Connor, C. M., Psotka, M. A., Fiuzat, M., Lindenfeld, J. M., Abraham, W. T., Bristow, M. R., Caños, D., Harrington, R. A., Hillebrenner, M., Jessup, M. L., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.048 · Cited by 53
“Recently, rare successes in new molecular entity development have been greeted by slow physician uptake and prescribing, limiting the ability of sponsors to recoup their financial investment (19).”
BackgroundSelf-citationDiagnostic concordance between NT-proBNP and BNP for suspected heart failure
Farnsworth, C. W., Bailey, A. L., Jaffe, A. S., & Scott, M. G. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.07.002 · Cited by 54
Sex differences in ischemic heart disease and heart failure biomarkers
Sobhani, K., Castro, D. K. N., Fu, Q., Gottlieb, R. A., Eyk, J. E. V., & Merz, C. N. B. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0201-y · Cited by 60
Ambrosy, A. P., D, E. B. M., Morrow, D. A., DeVore, A. D., McCague, K., Meng, X., Duffy, C. I., Rocha, R., & Velazquez, E. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.073 · Cited by 50
Khan, M. S., Felker, G. M., Piña, I. L., Camacho, A., Bapat, D., Ibrahim, N. E., Maisel, A. S., PRESCOTT, M. F., Ward, J. H., Solomon, S. D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.09.014 · Cited by 56
Self-citationWnt Signaling in Cardiac Disease
Hermans, K. C. M., & Blankesteijn, W. M. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140060 · Cited by 61
Impact of cardiovascular hemodynamics on cognitive aging
Moore, E. E., & Jefferson, A. L. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311909 · Cited by 49
Yang, C., Chen, Y.-T., Chen, C., Li, Y., Shao, P., Huang, T.-H., Chen, Y., Sun, C., & Yip, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108954 · Cited by 50
Rezq, A., Saad, M. S., & Nozahi, M. E. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.037 · Cited by 51
Drug Layering in Heart Failure
Rosano, G. M. C., Allen, L. A., Abdin, A., Lindenfeld, J. M., O’Meara, E., Lam, C. S. P., Lancellotti, P., Savarese, G., Gottlieb, S. S., Teerlink, J. R., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.011 · Cited by 55
Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
Curtain, J. P., Jackson, A. M., Shen, L., Jhund, P. S., Docherty, K. F., Petrie, M. C., Castagno, D., Desai, A. S., Rohde, L. E. P., Lefkowitz, M. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2419 · Cited by 54
“Two time-to-first event ventricular arrhythmia outcomes were examined: (1) any ventricular arrhythmia, and (2) the composite of a ventricular arrhythmia, resuscitated cardiac arrest or an ICD discharge.”
MethodSelf-citationEgbe, A. C., Miranda, W. R., Pellikka, P. A., DeSimone, C. V., & Connolly, H. M. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.040 · Cited by 53
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
Carberry, J., Marquis‐Gravel, G., O’Meara, E., & Docherty, K. F. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.025 · Cited by 49
Roksnoer, L. C. W., van Veghel, R., VRIES, R. D., Garrelds, I. M., Bhaggoe, U. M., Friesema, E. C. H., Leijten, F. P. J., Poglitsch, M., Domenig, O., Groningen, M. C. C., et al. (2015) · Kidney International · doi:10.1038/ki.2015.107 · Cited by 57
Biomarkers in Acute Heart Failure
Mallick, A., & Januzzi, J. L. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.02.009 · Cited by 60
“In the recent landmark PARADIGM–HF trial,(24) use of LCZ696 (an agent containing a neprilysin inhibitor) was superior to enalapril for the care of patients with chronic HF.(24) Treatment with LCZ696 resulted in significantly higher BNP concentrations, part of the therapeutic effect of the drug(25); NT–proBNP is not a…”
BackgroundKloppe, A., Lawo, T., Mijić, D., Schiedat, F., Muegge, A., & Lemke, B. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.001 · Cited by 49
“The recently published PARADIGM-HF study [16] has followed patients with similar heart failure condition (mostly NYHA II–III, mean EF 29.”
BackgroundMethodSemenov, A. G., & Katrukha, A. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.254524 · Cited by 50
Tsutsui, H., Momomura, S., Saito, Y., Ito, H., Yamamoto, K., Ohishi, T., Okino, N., & Guo, W. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.11.011 · Cited by 50
“LCZ696 was well-tolerated and the overall frequency of adverse events was comparable to enalapril [15].”
BackgroundResultIzzo, J. L., Zappe, D., Jia, Y., Hafeez, K., & Zhang, J. Y. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000485 · Cited by 52
Zaman, S. U., Zaman, S., Scholtes, T., Shun-Shin, M. J., Plymen, C. M., Francis, D. P., & Cole, G. D. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.838 · Cited by 49
Hohendanner, F., Messroghli, D., Bode, D., Blaschke, F., Parwani, A. S., Boldt, L., & Heinzel, F. R. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12260 · Cited by 59
Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease
Lluri, G., Lin, J. P., Reardon, L. C., Miner, P. D., Whalen, K. M., & Aboulhosn, J. (2019) · World Journal for Pediatric and Congenital Heart Surgery · doi:10.1177/2150135119825599 · Cited by 49
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 54
Wang, C. C., Wu, C., Tsai, M., Lee, C., Huang, W. C., Chou, H., Huang, J. L., Chi, N., Yen, H., Tzeng, B., et al. (2019) · PubMed Central · doi:10.6515/acs.201905_35(3).20190422a · Cited by 54
Han, X., Liu, P., Liu, M., Wei, Z., Fan, S., Wang, X., Sun, S., & Chu, L. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000003 · Cited by 52
Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes
Gulsin, G. S., Henson, J. J., Brady, E. M., Sargeant, J. A., Wilmot, E. G., Athithan, L., Htike, Z. Z., Marsh, A.-M., Biglands, J. D., Kellman, P., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0706 · Cited by 50
“While diastolic dysfunction has long been considered a central mechanism driving HFpEF, the role of microvascular inflammation and endothelial dysfunction is now increasingly being recognized (27).”
InfluentialIs Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
Sarrias, A., & Bayés‐Genís, A. (2018) · Circulation · doi:10.1161/circulationaha.118.034755 · Cited by 49
DeVore, A. D., Hill, C. L., Thomas, L. E., Sharma, P. P., Albert, N. M., Butler, J., Patterson, J. H., Spertus, J. A., Williams, F. B., Duffy, C. I., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.005400 · Cited by 49
Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy
Dannenberg, L., Zikeli, D., Benkhoff, M., Ahlbrecht, S., Kelm, M., Levkau, B., & Polzin, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107584 · Cited by 55
Rosano, G. M. C., Vitale, C., Adamo, M., & Metra, M. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001221 · Cited by 55
da Silva, I. G. R., Pantoja, B. T. D. S., Almeida, G. H. D. R., Carreira, A. C. O., & Miglino, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073955 · Cited by 53
“Although pharmacological treatments of β-blockers and angiotensin-converting enzyme (ACE) inhibitors [46,47] are beneficial for patients with MI, these existing approaches require exploring new treatment methods aimed at regenerating the infarcted myocardium, as well as their implementation in clinical practice [48].”
BackgroundEscobar, C., Palacios, B., Varela, L. F., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175199 · Cited by 56
“However, it should be taken into account that although current guidelines recommend as first-line therapy the use of ARNI (preferably)/ACEi, beta blockers, aldosterone antagonists, and SGLT2i [1], the PARADIGM-HF trial was published in 2014 [13] and the DAPA-HF, EMPEROR-Reduced, and SOLOIST-WHF trials were published i…”
BackgroundMathews, L. M., Ding, N., Mok, Y., Shin, J., Crews, D. C., Rosamond, W. D., Newton, A., Chang, P. P., Ndumele, C. E., Coresh, J., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024057 · Cited by 54
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 51
“Diabetes has a serious prognostic value in HF [41,42].”
BackgroundHeart failure and diabetes: Understanding the bidirectional relationship
Elendu, C., Amaechi, D. C., Elendu, T. C., Ashna, M., Ross-Comptis, J., Ansong, S. O., Egbunu, E. O., Okafor, G. C., Jingwa, K. A., Akintunde, A. A., et al. (2023) · Medicine · doi:10.1097/md.0000000000034906 · Cited by 60
Patel, R., Sharma, A., Prasad, A., & Bansal, S. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100705 · Cited by 65
Gan, L., Langenickel, T., Petruck, J., Kode, K., Rajman, I., Chandra, P., Zhou, W., Rebello, S. S., & Sunkara, G. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.571 · Cited by 47
“Efficacy results also showed that LCZ696 was effective in treating elderly patients with HF.”
BackgroundMethodInfluentialCalming the Nervous Heart: Autonomic Therapies in Heart Failure
Hanna, P., Shivkumar, K., & Ardell, J. L. (2018) · Cardiac failure review · doi:10.15420/cfr.2018.20.2 · Cited by 51
“However, despite improvements in pharmacologic approaches, treatment of HF remains challenging.(9,10) Neuromodulation therapy to restore sympathovagal balance in HF has garnered increasing interest in recent years.”
BackgroundAppadurai, V., Thoreau, J., Malpas, T., & Nicolae, M. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.12.003 · Cited by 50
New perspectives and future directions in the treatment of heart failure
Pellicori, P., Khan, M. J., Graham, F. J., & Cleland, J. G. F. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09829-7 · Cited by 56
Kim, K.-J., Cho, H., Kim, M., Kang, J., Kim, K., Kim, D., Seo, S. M., Yang, J. H., Cha, M., Choi, J., et al. (2019) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0002 · Cited by 50
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.